Pharmaxis touts progress in cystic fibrosis study

By Ruth Beran
Monday, 19 December, 2005

Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.

The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being conducted at two sites in the UK.

The 42 patients enrolled in the study will receive three months treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life.

Full patient recruitment is expected to take about eight months

Related News

Oxytocin analogue treats chronic abdominal pain

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd